"Clearly, this is an exciting opportunity for Rosetta. Altos Solutions is the first U.S. company to offer oncology practices a platform of integrated, knowledge-based products and services to collect, benchmark and analyze data. We look forward to the initial rollout of this integration, starting this month, to the entire network of oncology physicians who utilize OncoEMR, and completion of the integration by the end of November. We expect these solutions to further enhance the awareness and utilization of our Cancer Origin Test as we continue to focus on driving demand for testing services," concluded Mr. Berlin.
The company on Oct. 15 announced that participants at the International Association for the Study of Lung Cancer’s (IALSC) 15th World Conference on Lung Cancer to be held October 27 – 30, 2013 in Sydney, Australia will discuss novel immunotherapy checkpoint inhibitors including Peregrine’s novel target phosphatidylserine (PS). The conference is the world’s largest meeting dedicated to lung cancer and other thoracic malignancies and brings together more than 5,000 delegates from across the medical and scientific professional spectrums from more than 100 countries.